GLP-1-induced gastroparesis

Gastroparesis means the stomach empties far too slowly without any physical blockage. Food sits. The result is nausea hours after eating, vomiting undigested food, early fullness after a few bites, bloating and upper abdominal pain. On a GLP-1 the label language for the mild version is simply “delays gastric emptying” — the clinical syndrome is that effect taken further than anyone wanted.

Every label in the category states that the drug delays gastric emptying, and the severe end of the spectrum appears in the postmarketing sections as ileus, intestinal obstruction and severe constipation including fecal impaction. Postmarketing reports come from a population of unknown size, so no frequency can be attached — a real limitation, not a reassurance. A 2023 population study in JAMA brought these gastrointestinal events into mainstream attention by examining their occurrence in people using GLP-1 agonists for weight loss.

The most useful mechanistic detail sits in the Zepbound label: the delay in gastric emptying is largest after the first dose and diminishes over time. That is why symptoms typically peak in the days after starting or after a dose increase, and why holding at your current dose often resolves what a dose increase created.

The confusion that matters is separating ordinary GLP-1 nausea from something that needs evaluation. Nausea that comes on after a large or fatty meal and settles is expected. Vomiting food you ate the previous day, being unable to keep fluids down, or losing weight through inability to eat rather than reduced appetite is a different problem and warrants a call.

There is also a real safety consequence before sedation, covered in our anesthesia entry. Ask your clinician what symptoms should trigger a dose hold versus an urgent visit, and whether smaller, lower-fat meals would help before changing the dose. Our gastroparesis review and side-effect timeline go further.